Outcome of adolescents and young adults with acute lymphoblastic leukemia in a single center in Brazil.

Autor:	Aguiar TF; Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil; Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti, Rio de Janeiro, RJ, Brazil., da Conceição Barbosa T; Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil., Maciel ALT; Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil., Blunck CB; Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil., Sellos-Laclette J; Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil., de Melo AC; Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil., Mansur MB; Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil; Children's Hospital, John Radcliffe Hospital, Oxford, UK; Weatherall Institute of Molecular Medicine -WIMM, University of Oxford, Oxford, UK., Emerenciano M; Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil. Electronic address: memerenciano@inca.gov.br.
Jazyk:	angličtina
Zdroj:	Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2023 Jul; Vol. 45 Suppl 2, pp. S108-S112. Date of Electronic Publication: 2022 Aug 01.
DOI:	10.1016/j.htct.2022.06.006
Abstrakt:	Introduction: Acute lymphoblastic leukemia (ALL) presents a poor prognosis in adults. The adoption of pediatric protocols has been changing this scenario, especially for adolescents and young adults (AYA). Objective and Method: We aimed to evaluate a consecutive series of patients treated at the State Institute of Hematology of Rio de Janeiro between 2012 and 2020, focusing on the AYA subgroup. Result: The B-ALL was the most frequent subtype (81.6%) and AYA, the predominant age group (57.7%). The median overall survival (OS) was 9.4 months. High early mortality was observed and sepsis was the main cause of death. Better OS results were noted in AYA, in comparison to over 39y (13.3 × 6.2 months, respectively), the Berlin-Frankfurt-Münster (BFM) being the protocol of choice in this group. Conclusion: The use of the pediatric protocol seems to improve the OS of AYA, however, high rates of deaths from infection were observed, demonstrating the need for advances in the Brazilian public system clinical support. Competing Interests: Conflicts of interest None. (Copyright © 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu